Molecular characterization of resected non-metastatic pancreatic cancer (PC) based on <i>KRAS</i> status.
Angelo Pirozzi(Humanitas University), Tanios S. Bekaii-Saab(WinnMed), Oluseyi Abidoye(Mayo Clinic), Taro Shibuki(National Cancer Center Hospital East), Mitesh J. Borad(Jacksonville College), Binbin Zheng-Lin(WinnMed), Cody Eslinger(WinnMed), Mohamad Bassam Sonbol(WinnMed), Ellen Jaeger(Tempus Labs (United States)), Matina Fragkogianni(Tempus Labs (United States)), Arya Ashok(Tempus Labs (United States)), Celine Hoyek(Mayo Clinic Hospital), Daniel H. Ahn(WinnMed), Christina Wu(WinnMed), Masafumi Ikeda(National Cancer Center Hospital East), Takayuki Yoshino(National Cancer Center Hospital East), John Strickler(Duke Medical Center), Lorenza Rimassa(Humanitas University), Unnati Jariwala
Cited by 0
Related Papers
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
|Cell Reports|2017|619
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423
Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
|PLoS Genetics|2014|341
Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis
|The Journal of Clinical Endocrinology & Metabolism|2015|328